Business-development momentum can make every open issue look like something to solve later. In pharmaceutical work, some uncertainties must be resolved before confidential transfer, engineering batches, validation, registration commitments or supply promises begin.
1. The proposed legal entity or manufacturing scope cannot be verified
A brand name, group relationship or general capability deck is not enough. The project must identify the exact authorization holder, contract manufacturer, site, licensed scope and target-market roles.
Hold until the parties can map the legal and regulatory pathway to current evidence.
2. Product-process-facility fit remains speculative
A dosage-form match does not answer scale, sterilization, aseptic handling, containment, packaging, analytical, cleaning or co-line questions. If facility fit depends on assumptions that cannot be tested, the project is not ready for commitment.
3. Critical knowledge has no accountable owner
Transfers fail when essential rationale is dispersed among former employees, third-party developers, suppliers or incomplete files. The project needs an accountable source of product and process knowledge and a plan for resolving unknowns.
4. Quality responsibilities or evidence access cannot be agreed
If the parties cannot agree notification, deviation, change, release, audit, record access and inspection support, execution will magnify the disagreement. Governance must be operational before quality-critical work.
5. The schedule requires bypassing evidence
A requested launch date cannot replace method transfer, engineering work, validation, stability, filing or authority interaction. Compress activities only when risk and requirements permit; do not remove the evidence needed for the decision.
6. Commercial assumptions depend on guarantees that cannot be made
Guaranteed approval, unconditional capacity, fixed timing before scope, or demand forecasts without accountable inputs create a fragile project. Reframe the proposal around assumptions, dependencies and decision ranges.
7. Confidentiality and data controls are not ready
Do not accept formulas, patient data, complete dossiers or trade secrets through an unrestricted first-contact channel. Pause the exchange until the NDA, request list, authorized users, data room and retention rules are defined.
A four-part test for resuming
Resume only when the issue has a named owner, required evidence, acceptance criteria and a decision date. If one of the four is missing, the project may still be discussing the problem rather than controlling it.
Frequently asked questions
Is placing a project on hold the same as rejecting it?
No. A hold identifies a decision condition that has not yet been satisfied. The project may resume when the condition is controlled.
Who should approve a hold?
The accountable business, technical, quality and regulatory owners should follow an agreed governance route appropriate to the risk.
Can commercial urgency override a hold?
Urgency can change resources and sequencing, but it should not remove required evidence, validation or legal responsibility.
How should the reason be documented?
Record the unresolved risk, owner, evidence required, acceptance criteria, dependencies and next decision date.
Authoritative sources
This article is an industry decision framework for general business discussion. It is not legal, regulatory or medical advice and does not describe a named client case.